Syngeneic mouse tumour models have frequently been used to profile immune responses in tumours, CRL have optimized and profiled existing check-point inhibitors to support immuno-oncology drug discovery using mouse and rat antibody variants of anti-CTLA4 and anti-PD1. Here, CTLA4 is linked to neoplasm.